Oscar Ã– Braun

List of Publications by Year
in descending order

34 papers	1,760 citations	430874 18 h-index	395702 33 g-index
34 all docs	34 docs citations	34 times ranked	2665 citing authors

#	Article	IF	Citations
1	Improved survival of left ventricular assist device carriers in <scp>Europe</scp> according to implantation eras: results from the <scp>PCHFâ€VAD</scp> registry. European Journal of Heart Failure, 2022, 24, 1305-1315.	7.1	10
2	Outcome of patients on heart transplant list treated with a continuous-flow left ventricular assist device: Insights from the TRans-Atlantic registry on VAd and TrAnsplant (TRAViATA). International Journal of Cardiology, 2021, 324, 122-130.	1.7	8
3	Characteristics and outcomes in patients with atrial fibrillation and acute coronary syndrome treated with ticagrelor and novel oral anticoagulants. Thrombosis Update, 2021, 3, 100054.	0.9	0
4	Improved Time in Therapeutic Range with International Normalized Ratio Remote Monitoring for Patients with Left Ventricular Assist Devices. ASAIO Journal, 2021, Publish Ahead of Print, .	1.6	3
5	Cardiovascular implantable electronic device therapy in patients with left ventricular assist devices: insights from TRAViATA. International Journal of Cardiology, 2021, 340, 26-33.	1.7	4
6	Intraventricular Flow Patterns in Patients Treated with Left Ventricular Assist Devices. ASAIO Journal, 2021, 67, 74-83.	1.6	14
7	Improving risk prediction in heart failure using machine learning. European Journal of Heart Failure, 2020, 22, 139-147.	7.1	132
8	Viral genome search in myocardium of patients with fulminant myocarditis. European Journal of Heart Failure, 2020, 22, 1277-1280.	7.1	19
9	Which advanced heart failure therapy strategy is optimal for patients over 60 years old?. Journal of Cardiovascular Surgery, 2019, 60, 251-258.	0.6	2
10	Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors. Scandinavian Cardiovascular Journal, 2019, 53, 14-20.	1.2	5
11	Management of RVAD Thrombosis in Biventricular HVAD Supported Patients: Case Series. ASAIO Journal, 2019, 65, e36-e41.	1.6	11
12	The value of Stanford integrated psychosocial assessment for transplantation (SIPAT) in prediction of clinical outcomes following left ventricular assist device (LVAD) implantation. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 85-89.	1.6	28
13	Caffeine and incidence of dyspnea in patients treated with ticagrelor. American Heart Journal, 2018, 200, 141-143.	2.7	4
14	Neutrophil extracellular trap-microparticle complexes enhance thrombin generation via the intrinsic pathway of coagulation in mice. Scientific Reports, 2018, 8, 4020.	3.3	88
15	Emergency department visits among patients with left ventricular assist devices. Internal and Emergency Medicine, 2018, 13, 907-913.	2.0	21
16	Plateletâ€derived microparticles regulates thrombin generation via phophatidylserine in abdominal sepsis. Journal of Cellular Physiology, 2018, 233, 1051-1060.	4.1	39
17	Management of Arrhythmias and Cardiac Implantable Electronic Devices in PatientsÂWithÂLeft Ventricular Assist Devices. JACC: Clinical Electrophysiology, 2018, 4, 847-859.	3.2	16
18	Blood lactate is a predictor of short-term mortality in patients with myocardial infarction complicated by heart failure but without cardiogenic shock. BMC Cardiovascular Disorders, 2018, 18, 8.	1.7	31

#	Article	IF	Citations
19	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	3.9	177
20	Rac1 regulates bacterial toxin-induced thrombin generation. Inflammation Research, 2016, 65, 405-413.	4.0	4
21	Monocytes regulate systemic coagulation and inflammation in abdominal sepsis. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H540-H547.	3.2	22
22	Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. American Heart Journal, 2015, 170, 465-470.	2.7	11
23	Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thrombosis Research, 2015, 135, 26-30.	1.7	58
24	Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets, 2014, 25, 257-263.	2.3	45
25	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart, 2014, 100, 1762-1769.	2.9	38
26	Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thrombosis and Haemostasis, 2013, 110, 1223-1231.	3.4	12
27	Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention, 2012, 8, 672-678.	3.2	73
28	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European Heart Journal, 2009, 30, 1744-1752.	2.2	231
29	Platelets support pulmonary recruitment of neutrophils in abdominal sepsis*. Critical Care Medicine, 2009, 37, 1389-1396.	0.9	132
30	Primary and secondary capture of platelets onto inflamed femoral artery endothelium is dependent on P-selectin and PSGL-1. European Journal of Pharmacology, 2008, 592, 128-132.	3.5	21
31	Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thrombosis and Haemostasis, 2008, 100, 626-633.	3.4	70
32	Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. European Heart Journal, 2007, 29, 21-30.	2.2	408
33	Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y1 and the P2Y12 receptor and is correlated with protein expression of P2Y12. Purinergic Signalling, 2007, 3, 195-201.	2.2	16
34	Increased platelet purinergic sensitivity in peripheral arterial disease â€“ A pilot study. Platelets, 2005, 16, 261-267.	2.3	7